comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 15:59:18 - browse：5

Medicare and money photo illustration. — Adobe

WASHINGTON — A week after the Food and Drug Administration granted full, traditional approval to a new Alzheimer’s treatment, insurers are finalizing their plans to cover it as well as associated scans and diagnostic tests.

Medicare will cover most patients eligible for Leqembi, a new treatment developed by Eisai and Biogen to help slow the progression of Alzheimer’s disease. The drug, which has modest benefits, has potentially serious side effects for some patients including brain swelling and bleeding.

Medicare told STAT that it would cover brain scans and genetic testing that will help screen for and monitor potential side effects. Medicare already covers one amyloid PET scan per lifetime, but the agency is reconsidering that policy and plans to release a new proposed policy “soon,” an agency spokesperson said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Gov. Ron DeSantis' push for 'civics' education: What does it look like?

explore

WSS

Pope Francis asks Church to identify 21st

Pope Francis asks Church to identify 21st

How to increase colonoscopy rates? Looks like an AI can help

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Let's speed up science by embracing open access publishing

How to increase colonoscopy rates? Looks like an AI can help

knowledge

comprehensive

knowledge

Sports medicine is finally prioritizing gender equality

Condition critical? Britain's beloved but battered National Health Service turns 75

Supreme Court strikes down use of affirmative action

With trial win, GSK could get blood cancer drug back on market

BioMarin wins approval for gene therapy to treat hemophilia A

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Cancer drug shortages should be causing more outrage

Shifting the focus from loneliness to social health

Medical records are filled with copy

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

focus

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Cord blood banking comes at a high cost to babies

EU moves toward latest gene techniques in food production to counter climate change, shortages

Ionis drug prevents swelling attacks due to hereditary angioedema

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

Condition critical? Britain's beloved but battered National Health Service turns 75

leisure time

explore

knowledge

leisure time